The Pharmacy and Poisons Board, has cautioned against the use, distribution, issuing, and sale of three batches of paracetamol 1000mg/100ml injection, one batch of Sprazo(Esomeprazole 40mg), one batch of Augmentin 1G and two batches of Augmentin 625 MG, which have been identified as substandard.
The three batches of paracetamol include Lumidol Injection: Batch Numbers CM4594007, CM4594008, and CM4594009, manufactured by KamlaAmrut Pharmaceutical India; Blink Injection: Batch Numbers CS4594005 and CS4594004, manufactured by KamlaAmrut Pharmaceutical India; and Paragen Injection: Batch Number K4290027, manufactured by KamlaAmrut Pharmaceutical India.
In a statement on Thursday, April 24, the PPB CEO, Fred Siyoi, said that the paracetamols have exhibited colour change, thus raising quality concerns.
The board has further recalled S-Prazo (Esomeprazole 40mg) Batch No. SPZ404, manufactured by Medico Remedies Pharmaceutical India, after the board detected a strip of Levofloxacin 500 mg tablets in a pack of Esomeprazole 40mg capsules.
"In execution of the foregoing mandate, the Board draws public attention to the detection of a product mix-up involving S-Prazo (Esomeprazole 40mg), Batch No. SPZ404, wherein it was reported and confirmed that a strip of Levofloxacin 500mg tablets was found in a pack of Esomeprazole 40mg capsules," he said.
Lastly, the Board has also cautioned against the use and sale of Augmentin 1G Batch Number SHS2 and Augmentin 625MG Batch Numbers 8X3K and EU7C, which, according to the Board, were falsified in the market.
"In execution of the foregoing mandate, the Board draws public attention to the detection of falsified Augmentin 1G Batch SHS2 and Augmentin 625MG Batch Numbers: 8X3K and EU7C in the Kenyan market," he said.
Augmentin drugs are used as antibiotics, S-Prazo drugs are used to treat conditions related to stomach acid and ulcers, while paracetamol is used to relieve pain and reduce fever.
Siyoi has directed that anyone with the said medicines should immediately return them to the nearest healthcare facility or supplier.
"Given the above, the Board advises all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to IMMEDIATELY CEASE further distribution, sale, issuing, or use of the outlined product batches and return the same to their nearest healthcare facility or respective suppliers," he said.
Siyoi has further urged the public to remain vigilant and report cases of substandard medicines or drug reactions to the Board or the nearest healthcare facility.
The announcements come weeks after the board, in a statement on Monday, March 11, lifted the quarantine order on Mefnac Oral Suspension (Mefenamic Acid 50mg/5ml) after four months of probe into safety concerns.
